RALOXIFENE GxP Raloxifene hydrochloride 60 mg tablets, blister pack

Country: Ավստրալիա

language: անգլերեն

source: Department of Health (Therapeutic Goods Administration)

active_ingredient:

raloxifene hydrochloride, Quantity: 60 mg

MAH:

MedTAS Pty Ltd

INN:

Raloxifene hydrochloride

pharmaceutical_form:

Tablet, film coated

composition:

Excipient Ingredients: microcrystalline cellulose; crospovidone; magnesium stearate; glycine; colloidal anhydrous silica; polysorbate 80; povidone; titanium dioxide; hypromellose; Carnauba Wax; macrogol 400

administration_route:

Oral

units_in_package:

28 tablets

prescription_type:

(S4) Prescription Only Medicine

therapeutic_indication:

Raloxifene is indicated for the prevention and treatment of osteoporosis in post-menopausal women.,Raloxifene is indicated for the reduction in the risk of invasive breast cancer in postmenopausal women with osteoporosis.Raloxifene is indicated for the reduction in the risk of invasive breast cancer in postmenopausal women at high risk of invasive breast cancer.

leaflet_short:

Visual Identification: White to off-white, oval, biconvex, film coated tablets with 'C' on one side and '12' on other side.; Container Type: Blister Pack; Container Material: Al/Al; Container Life Time: 24 Months; Container Temperature: Store below 25 degrees Celsius

authorization_status:

Licence status A

authorization_date:

2014-01-14